R‑spondin family members as novel biomarkers and prognostic factors in lung cancer

Wu,Lingzhi; Zhang,Weili; Qian,Jinxian; Wu,Jian; Jiang,Liyang; Ling,Chunhua

doi:10.3892/ol.2019.10778

R‑spondin family members as novel biomarkers and prognostic factors in lung cancer

Authors:
- Lingzhi Wu
- Weili Zhang
- Jinxian Qian
- Jian Wu
- Liyang Jiang
- Chunhua Ling
View Affiliations

Affiliations: Department of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China, Department of Gastroenterology, Xiangcheng People's Hospital, Suzhou, Jiangsu 215131, P.R. China, Department of Intensive Care Unit, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, Jiangsu 215008, P.R. China, Department of Respiratory Diseases, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China
Published online on: August 22, 2019 https://doi.org/10.3892/ol.2019.10778
Pages: 4008-4015
Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The R‑spondin (RSPO) family of secreted proteins consists of four members that have critical roles in embryonic development and organogenesis. However, the expression patterns and the exact roles of the individual RSPO family members in tumorigenesis and progression of lung cancer are unknown, particularly in non‑small cell lung cancer, which accounts for 85% of all lung cancer cases. In the present study, data from the ONCOMINE database was used to compare the RNA expression levels of RSPOs in multiple different types of cancer with normal controls. The expression profiles of RSPOs in various types of cancer cell lines were subsequently compared based on data from the Broad Institute Cancer Cell Line Encyclopedia. Using the Kaplan‑Meier plotter, the prognostic value of expression of the different RSPOs members was determined for different pathological subtypes of lung cancer. When compared with normal tissues, expression of RSPO1, RSPO2 and RSPO3 was significantly lower in patients with lung cancer. In the survival analysis, increased mRNA expression levels of RSPO1, RSPO2 and RSPO3 were associated with increased survival in patients with lung adenocarcinomas. These results suggest that RSPO1, RSPO2 and RSPO3 may serve as distinct biomarkers and prognostic factors in patients with lung cancer.

View Figures

View References

1	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
3	Moya-Horno I, Viteri S, Karachaliou N and Rosell R: Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC). Ther Adv Med Oncol. 10:17588340177450122018. View Article : Google Scholar : PubMed/NCBI
4	Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
5	Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, et al: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 368:2385–2394. 2013. View Article : Google Scholar : PubMed/NCBI
6	Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Børresen-Dale AL, et al: Signatures of mutational processes in human cancer. Nature. 500:415–421. 2013. View Article : Google Scholar : PubMed/NCBI
7	Puig de la Bellacasa R, Karachaliou N, Estrada-Tejedor R, Teixidó J, Costa C and Borrell JI: ALK and ROS1 as a joint target for the treatment of lung cancer: A review. Transl Lung Cancer Res. 2:72–86. 2013.PubMed/NCBI
8	Wen M, Wang X, Sun Y, Xia J, Fan L, Xing H, Zhang Z and Li X: Detection of EML4-ALK fusion gene and features associated with EGFR mutations in Chinese patients with non-small-cell lung cancer. Onco Targets Ther. 9:1989–1995. 2016. View Article : Google Scholar : PubMed/NCBI
9	Kim KA, Zhao J, Andarmani S, Kakitani M, Oshima T, Binnerts ME, Abo A, Tomizuka K and Funk WD: R-Spondin proteins: A novel link to beta-catenin activation. Cell Cycle. 5:23–26. 2006. View Article : Google Scholar : PubMed/NCBI
10	Kazanskaya O, Glinka A, del Barco Barrantes I, Stannek P, Niehrs C and Wu W: R-Spondin2 is a secreted activator of Wnt/beta-catenin signaling and is required for Xenopus myogenesis. Dev Cell. 7:525–534. 2004. View Article : Google Scholar : PubMed/NCBI
11	de Lau WB, Snel B and Clevers HC: The R-spondin protein family. Genome Biol. 13:2422012. View Article : Google Scholar : PubMed/NCBI
12	Rong X, Chen C, Zhou P, Zhou Y, Li Y, Lu L, Liu Y, Zhou J and Duan C: R-spondin 3 regulates dorsoventral and anteroposterior patterning by antagonizing Wnt/β-catenin signaling in zebrafish embryos. PLoS One. 9:e995142014. View Article : Google Scholar : PubMed/NCBI
13	Sher I, Yeh BK, Mohammadi M, Adir N and Ron D: Structure-based mutational analyses in FGF7 identify new residues involved in specific interaction with FGFR2IIIb. FEBS Lett. 552:150–154. 2003. View Article : Google Scholar : PubMed/NCBI
14	Zebisch M, Xu Y, Krastev C, MacDonald BT, Chen M, Gilbert RJ, He X and Jones EY: Structural and molecular basis of ZNRF3/RNF43 transmembrane ubiquitin ligase inhibition by the Wnt agonist R-spondin. Nat Commun. 4:27872013. View Article : Google Scholar : PubMed/NCBI
15	Kim KA, Wagle M, Tran K, Zhan X, Dixon MA, Liu S, Gros D, Korver W, Yonkovich S, Tomasevic N, et al: R-Spondin family members regulate the Wnt pathway by a common mechanism. Mol Biol Cell. 19:2588–2596. 2008. View Article : Google Scholar : PubMed/NCBI
16	Planas-Paz L, Orsini V, Boulter L, Calabrese D, Pikiolek M, Nigsch F, Xie Y, Roma G, Donovan A, Marti P, et al: The RSPO-LGR4/5-ZNRF3/RNF43 module controls liver zonation and size. Nat Cell Biol. 18:467–479. 2016. View Article : Google Scholar : PubMed/NCBI
17	Kazanskaya O, Ohkawara B, Heroult M, Wu W, Maltry N, Augustin HG and Niehrs C: The Wnt signaling regulator R-spondin 3 promotes angioblast and vascular development. Development. 135:3655–3664. 2008. View Article : Google Scholar : PubMed/NCBI
18	Seshagiri S, Stawiski EW, Durinck S, Modrusan Z, Storm EE, Conboy CB, Chaudhuri S, Guan Y, Janakiraman V, Jaiswal BS, et al: Recurrent R-spondin fusions in colon cancer. Nature. 488:660–664. 2012. View Article : Google Scholar : PubMed/NCBI
19	Han T, Schatoff EM, Murphy C, Zafra MP, Wilkinson JE, Elemento O and Dow LE: R-spondin chromosome rearrangements drive Wnt-dependent tumour initiation and maintenance in the intestine. Nat Commun. 8:159452017. View Article : Google Scholar : PubMed/NCBI
20	Zhou X, Geng L, Wang D, Yi H, Talmon G and Wang J: R-spondin1/LGR5 activates TGFβ signaling and suppresses colon cancer metastasis. Cancer Res. 77:6589–6602. 2017. View Article : Google Scholar : PubMed/NCBI
21	Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV, Sonkin D, et al: The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 483:603–607. 2012. View Article : Google Scholar : PubMed/NCBI
22	Cancer facts and figures 2008American Cancer Society; Atlanta, GA, USA: pp. 9–14. 2008
23	Hashimoto T, Ogawa R, Yoshida H, Taniguchi H, Kojima M, Saito Y and Sekine S: EIF3E-RSPO2 and PIEZO1-RSPO2 fusions in colorectal traditional serrated adenoma. Histopathology. 75:266–273. 2019. View Article : Google Scholar : PubMed/NCBI
24	Xing Y, Clements WK, Kimelman D and Xu W: Crystal structure of a beta-catenin/axin complex suggests a mechanism for the beta-catenin destruction complex. Genes Dev. 17:2753–2764. 2003. View Article : Google Scholar : PubMed/NCBI
25	Binnerts ME, Kim KA, Bright JM, Patel SM, Tran K, Zhou M, Leung JM, Liu Y, Lomas WE III, Dixon M, et al: R-Spondin1 regulates Wnt signaling by inhibiting internalization of LRP6. Proc Natl Acad Sci USA. 104:14700–14705. 2007. View Article : Google Scholar : PubMed/NCBI
26	Szenker-Ravi E, Altunoglu U, Leushacke M, Bosso-Lefèvre C, Khatoo M, Thi Tran H, Naert T, Noelanders R, Hajamohideen A, Beneteau C, et al: RSPO2 inhibition of RNF43 and ZNRF3 governs limb development independently of LGR4/5/6. Nature. 557:564–569. 2018. View Article : Google Scholar : PubMed/NCBI
27	Papapietro O, Teatero S, Thanabalasuriar A, Yuki KE, Diez E, Zhu L, Kang E, Dhillon S, Muise AM, Durocher Y, et al: R-spondin 2 signalling mediates susceptibility to fatal infectious diarrhoea. Nat Commun. 4:18982013. View Article : Google Scholar : PubMed/NCBI
28	Ilmer M, Boiles AR, Regel I, Yokoi K, Michalski CW, Wistuba II, Rodriguez J, Alt E and Vykoukal J: RSPO2 enhances canonical Wnt signaling to confer stemness-associated traits to susceptible pancreatic cancer cells. Cancer Res. 75:1883–1896. 2015. View Article : Google Scholar : PubMed/NCBI
29	Vidal V, Sacco S, Rocha AS, da Silva F, Panzolini C, Dumontet T, Doan TM, Shan J, Rak-Raszewska A, Bird T, et al: The adrenal capsule is a signaling center controlling cell renewal and zonation through Rspo3. Genes Dev. 30:1389–1394. 2016. View Article : Google Scholar : PubMed/NCBI
30	Storm EE, Durinck S, de Sousa e Melo F, Tremayne J, Kljavin N, Tan C, Ye X, Chiu C, Pham T, Hongo JA, et al: Targeting PTPRK-RSPO3 colon tumours promotes differentiation and loss of stem-cell function. Nature. 529:97–100. 2015. View Article : Google Scholar : PubMed/NCBI
31	Hsu CK, Romano MT, Nanda A, Rashidghamat E, Lee JYW, Huang HY, Songsantiphap C, Lee JY, Al-Ajmi H, Betz RC, et al: Congenital anonychia and uncombable hair syndrome: Coinheritance of homozygous mutations in RSPO4 and PADI3. J Invest Dermatol. 137:1176–1179. 2017. View Article : Google Scholar : PubMed/NCBI